GIAN LIFE CARE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.26 INR | -1.07% |
|
-0.93% | +2.07% |
| Sales 2021 | 105M 1.25M 100M | Sales 2022 | 159M 1.91M 153M | Capitalization | 430M 5.15M 413M |
|---|---|---|---|---|---|
| Net income 2021 | 20M 240K 19.2M | Net income 2022 | 43M 516K 41.29M | EV / Sales 2021 | 0.62 x |
| Net Debt 2021 | 1.6M 19.19K 1.54M | Net cash position 2022 | 3.35M 40.22K 3.22M | EV / Sales 2022 | 2.68 x |
| P/E ratio 2021 |
3.15
x | P/E ratio 2022 |
9.83
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 42.07% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.07% | ||
| 1 week | -0.93% | ||
| Current month | -17.17% | ||
| 1 month | -16.86% | ||
| 3 months | -6.68% | ||
| 6 months | -1.03% | ||
| Current year | +2.07% |
1 week
19.99
21.98
1 month
19.2725.07
Current year
18.5029.00
1 year
18.1629.00
3 years
6.8265.91
5 years
5.4865.91
10 years
5.4865.91
| Managers | Title | Age | Since |
|---|---|---|---|
Arun Kumar Gupta
CEO | Chief Executive Officer | 61 | 05/11/18 |
Avani Gupta
DFI | Director of Finance/CFO | 57 | 05/11/18 |
Vanshul Asnani
CMP | Compliance Officer | 32 | 26/06/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Avani Gupta
DFI | Director of Finance/CFO | 57 | 05/11/18 |
Arun Kumar Gupta
CEO | Chief Executive Officer | 61 | 05/11/18 |
Rashika Agarwal
BRD | Director/Board Member | 31 | 05/11/18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 20.26 | -1.07% | 30,712 |
| 25/04/24 | 20.48 | -0.29% | 37,770 |
| 24/04/24 | 20.54 | +0.74% | 14,170 |
| 23/04/24 | 20.39 | -1.97% | 23,924 |
| 22/04/24 | 20.8 | +1.71% | 33,165 |
Delayed Quote Bombay S.E., April 26, 2024 at 11:00 am
More quotes
Gian Life Care Limited is an India-based company. The Company is engaged in the business of providing diagnostic and related healthcare tests and services in various cities connecting Kanpur and nearby areas. The Company offers a range of approximately 1,344 tests, which includes various tests ranging from biochemistry, clinical pathology, coagulation, cytogenetics, cytology and hematology, among others. The Company provides a range of diagnostic and related healthcare tests and services such as patient diagnosis, prevention and wellness diagnosis services to its patients and healthcare providers. The Company is focused on opening several diagnostics labs in various parts of the State. Its subsidiaries include Gian Path Lab (India) Pvt Ltd and Gian Satguru Pathology LLP. Its customers include individual patients, hospitals, other healthcare providers and corporate customers.
Calendar
27/05/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +2.07% | 2.51M | |
| -17.89% | 8.25B | |
| +39.20% | 3.57B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -12.61% | 1.81B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B |
- Stock Market
- Equities
- GIANLIFE Stock
